Vectus Biosystems faces delisting risk as asset sale proceeds may fall short of operational needs
Vectus Biosystems Limited's planned sale of its Renal Anti-Fibrotic Therapeutic Program to XORTX creates potential delisting risk if transaction proceeds prove insufficient for ongoing operations. The Australian biotech faces shareholder value erosion with medium likelihood but catastrophic severity if the deal fails to provide adequate capital runway.
ViaNews Editorial Team (Markets)•